Is tucatinib available abroad now?

Tucatinib (tucatinib) is a molecularly targeted drug for HER2-positive metastatic breast cancer. It inhibits the proliferation and spread of tumor cells by inhibiting the activity of HER2 receptors. Its mechanism of action mainly involves its selective inhibition of HER2 receptors. HER2 (human epidermal growth factor receptor 2) is a membrane receptor tyrosine kinase that is highly expressed in HER2-positive breast cancer.

InHER2-positive breast cancer, overexpression of HER2 can lead to abnormal proliferation and survival of tumor cells, making them resistant to traditional chemotherapy drugs. Tucatinib interferes with the normal function of the HER2 signaling pathway by binding to the HER2 receptor and inhibiting its activity. In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, the addition of tucatinib to trastuzumab and capecitabine produced better progression-free survival and overall survival outcomes than placebo, but the risk of diarrhea and elevated transaminase levels was higher with tucatinib.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug specifications150mg*60 tablets per box listed overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of Tucatinib produced in other countries. The price of 150mg*60 tablets per box produced by Laos pharmaceutical factory is around 6,400 RMB (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.